Screening ABL1 kinase domain mutations in patients with de novo Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL)

被引：1
|
作者：
Li, He [1 ]
Zhang, Wanhua [1 ]
Yi, Dongni [1 ]
Ye, Yuanxin [2 ]
Xiao, Xueqiu [3 ]
机构：
[1] Sichuan Univ, West China Hosp, Dept Hematol, Hematol Res Lab, 37 Guo Xue Xiang, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Peoples R China
[3] Sichuan Univ, West China Sch Med, Chengdu, Peoples R China
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷 / 04期
关键词：
CHRONIC MYELOID-LEUKEMIA; BCR-ABL; CLINICAL IMPACT; IMATINIB; RESISTANT; THERAPY;
D O I：
10.1080/10428194.2016.1225205
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1005 / 1007
页数：3
相关论文
共 50 条
  • [41] HETEROGENEITY OF GENOMIC FUSION OF BCR AND ABL IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA
    RUBIN, CM
    CARRINO, JJ
    DICKLER, MN
    LEIBOWITZ, D
    SMITH, SD
    WESTBROOK, CA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (08) : 2795 - 2799
  • [42] Immunophenotypic Comparison of Philadelphia Chromosome-Like to Philadelphia Chromosome-Positive (Ph plus ) B-Lymphoblastic Leukemia
    Choi, Sarah M.
    Shao, Lina
    Boyer, Daniel
    LABORATORY INVESTIGATION, 2018, 98 : 507 - 508
  • [43] The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment
    Thomas, Xavier
    Heiblig, Mael
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (11) : 1061 - 1070
  • [44] Immunophenotypic Comparison of Philadelphia Chromosome-Like to Philadelphia Chromosome-Positive (Ph plus ) B-Lymphoblastic Leukemia
    Choi, Sarah M.
    Shao, Lina
    Boyer, Daniel
    MODERN PATHOLOGY, 2018, 31 : 507 - 508
  • [45] A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL)
    Short, Nicholas James
    Jabbour, Elias
    Jain, Nitin
    Macaron, Walid
    Huang, Xuelin
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Daver, Naval Guastad
    Haddad, Fadi
    Zoghbi, Marianne
    Nasnas, Cedric Christophe
    Nasr, Lewis Fady
    Mayor, Ejiroghene
    Deen, Wuliamatu
    Thankachan, Jennifer
    Loiselle, Christopher
    Garris, Rebecca
    Konopleva, Marina
    Ravandi, Farhad
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Further improvement of outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) treated with imatinib-combined chemotherapy
    Ohno, R.
    Yanada, M.
    ANNALS OF HEMATOLOGY, 2008, 87 : S73 - S75
  • [47] Managing Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitors
    Ravandi, Farhad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (02): : 198 - 203
  • [48] Bcr-Abl tyrosine kinase domain mutations both pre-exist and develop during imatinib treatment and are responsible for resistance in patients with Philadelphia-Chromosome positive acute lymphoblastic leukemia (Ph plus ALL).
    Pfeifer, Heike
    Wassmann, Barbara
    Pavlova, Anna
    Wunderle, Lydia
    Brueck, Patrick
    Hochhaus, Andreas
    Hoelzer, Dieter
    Ottmann, Oliver
    BLOOD, 2006, 108 (11) : 192A - 193A
  • [49] Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Mathisen, Michael S.
    O'Brien, Susan
    Thomas, Deborah
    Cortes, Jorge
    Kantarjian, Hagop
    Ravandi, Farhad
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (03) : 187 - 194
  • [50] Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
    Piccaluga, Pier Paolo
    Paolini, Stefania
    Martinelli, Giovanni
    CANCER, 2007, 110 (06) : 1178 - 1186
12345